The US FDA recently conducted a Pre-Approval Inspection [PAI] of Torrent Pharmaceuticals' oral-oncology manufacturing facility at Bileshwarpura, Gujarat from March 13 to 17, 2023.
At the end of the inspection, the company has been issued a "Form 483" with 1 observation, which is procedural. The company will respond to the US FDA within the stipulated timeline and work closely with USFDA to address the observation at the earliest.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy